Experimental heart drug did not succeed in late-stage trial
Eoniis Pharmaceuticals and Novartis announced that the experimental drug Belacarson, which aimed to lower low-density lipoprotein (LDL) cholesterol levels in heart patients, failed in late-stage trials. Although the drug significantly and consistently reduced LDL cholesterol levels in line with previous studies, it did not succeed in decreasing the risk of death from heart disease, heart attacks, strokes, or the need for emergency procedures to restore blood flow, compared to a placebo. As a result, Eoniis's shares fell by 6% after hours, marking a setback in the hope for an effective treatment to reduce heart disease risks using this medication.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)